SNS-314 mesylate

Name: SNS-314 mesylate
Brand: MedChemExpress
SKU: HY-12003
Rating: 5.0 (2 reviews)

Cat. No.: HY-12003 Purity: 99.53%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively.

For research use only. We do not sell to patients.

SNS-314 mesylate Chemical Structure

CAS No. : 1146618-41-8

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 81	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 81	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 70	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 220	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 320	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 500	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of SNS-314 mesylate:

SNS-314 Get quote

2 Publications Citing Use of MCE SNS-314 mesylate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aurora Kinase Isoform Specific Products:

View All Isoforms

Aurora Kinase Aurora A Aurora B Aurora C

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

SNS-314 mesylate is a potent and selective aurora kinase inhibitor with IC₅₀s of 9, 31, and 6 nM for aurora A, B and C, respectively^[1].

IC₅₀ & Target^[1]

Aurora A

9 nM (IC₅₀)

Aurora B

31 nM (IC₅₀)

Aurora C

6 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	EC₅₀	< 16 nM Compound: 21, SNS-314	Cell cycle arrest in human HCT116 cells assessed as accumulation of 4N DNA phase after 16 hrs by FACS Cell cycle arrest in human HCT116 cells assessed as accumulation of 4N DNA phase after 16 hrs by FACS	[PMID: 18678489]
HCT-116	EC₅₀	< 16 nM Compound: 1c	Cell cycle arrest in human HCT116 cells assessed as accumulation of 4N DNA by FACS analysis Cell cycle arrest in human HCT116 cells assessed as accumulation of 4N DNA by FACS analysis	[PMID: 19646866]
HCT-116	EC₅₀	< 16 nM Compound: 21, SNS-314	Decrease in histone H3 phosphorylation in human HCT116 cells after 16 hrs by Western blot Decrease in histone H3 phosphorylation in human HCT116 cells after 16 hrs by Western blot	[PMID: 18678489]
HCT-116	EC₅₀	6 nM Compound: 11, SNS-314	Antiproliferative activity against human HCT116 cells assessed as BrdU incorporation after 72 hrs Antiproliferative activity against human HCT116 cells assessed as BrdU incorporation after 72 hrs	[PMID: 19320489]
HCT-116	EC₅₀	6 nM Compound: 1c	Antiproliferative activity against human HCT116 cells by BrdU incorporation assay Antiproliferative activity against human HCT116 cells by BrdU incorporation assay	[PMID: 19646866]

In Vitro

SNS-314 blocks proliferation in a broad panel of tumor cell lines (HCT116, A2780, PC-3, HeLa, MDA-MB-231, H-1299, and HT29) with IC₅₀ values ranging from 1.8 nM in A2780 ovarian cancer cells to 24 nM in HT29 colon cancer cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 leads to dose-dependent inhibition of histone H3 phosphorylation for at least 10 h. SNS-314 shows significant tumor growth inhibition in a dose dependent manner under a variety of dosing schedules including weekly, bi-weekly, and 5 days on/9 days off^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

527.04

Formula

C₁₉H₁₉ClN₆O₄S₃

CAS No.

1146618-41-8

Appearance

Solid

Color

White to light yellow

SMILES

O=C(NC1=CC=CC(Cl)=C1)NC2=NC=C(S2)CCNC3=C4C(C=CS4)=NC=N3.OS(C)(=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 150 mg/mL (284.61 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8974 mL	9.4869 mL	18.9739 mL
5 mM	0.3795 mL	1.8974 mL	3.7948 mL
10 mM	0.1897 mL	0.9487 mL	1.8974 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: 15 mg/mL (28.46 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 15 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (150.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.53%

Select Batch:

Data Sheet (275 KB) SDS (252 KB)

COA (248 KB) HNMR (327 KB) LCMS (125 KB)

Handling Instructions (2659 KB)

References

[1]. Oslob JD, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. [Content Brief]

[2]. Arbitrario JP, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. [Content Brief]

Kinase Assay ^[2]	A homogeneous time-resolved fluorescence (HTRF)-based biochemical IC₅₀ assay is used to test for the kinase activity of the three isoforms of Aurora (A, B, and C) in the presence of SNS-314. A biotin-conjugated histone H3 peptide is used as substrate. Aurora-A kinase (7.5 nM) is assayed in 10 mM Tris–HCl pH 7.2, 10 mM MgCl₂, 0.1% BSA, 0.05% Tween 20, 1 mM DTT, 120 nM biotinylated peptide ARTKQTARKSTGGKAPRKQLA-GGK-biotin, 6 μM ATP (2×the Km for the enzyme) for 1 h at 25°C. The reaction is stopped with 200 mM EDTA. Aurora-B and Aurora-C are assayed at 5 nM enzyme concentration, 120 nM biotinylated peptide, and 300 lM ATP (29 the K_m for the enzymes) for 1 h at 25°C^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[2]	HCT116 cells are treated with various concentrations of SNS-314 for 96 hours. cells are incubated with BrdU for 2 h at 37°C. Cell proliferation activity is evaluated by chemiluminescence detection of BrdU incorporated in DNA^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice: Tumor mice are treated with vehicle or SNS-314. Animals are weighed, monitored for signs or symptoms of toxic effects, and measured for tumor volumes twice weekly until an end point is met^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Oslob JD, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4880-4. [Content Brief] [2]. Arbitrario JP, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8974 mL	9.4869 mL	18.9739 mL	47.4347 mL
	5 mM	0.3795 mL	1.8974 mL	3.7948 mL	9.4869 mL
	10 mM	0.1897 mL	0.9487 mL	1.8974 mL	4.7435 mL
	15 mM	0.1265 mL	0.6325 mL	1.2649 mL	3.1623 mL
	20 mM	0.0949 mL	0.4743 mL	0.9487 mL	2.3717 mL
	25 mM	0.0759 mL	0.3795 mL	0.7590 mL	1.8974 mL
	30 mM	0.0632 mL	0.3162 mL	0.6325 mL	1.5812 mL
	40 mM	0.0474 mL	0.2372 mL	0.4743 mL	1.1859 mL
	50 mM	0.0379 mL	0.1897 mL	0.3795 mL	0.9487 mL
	60 mM	0.0316 mL	0.1581 mL	0.3162 mL	0.7906 mL
	80 mM	0.0237 mL	0.1186 mL	0.2372 mL	0.5929 mL
	100 mM	0.0190 mL	0.0949 mL	0.1897 mL	0.4743 mL

SNS-314 mesylate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SNS-3141146618-41-8SNS314SNS 314Aurora KinaseHCT116A2780PC-3HeLaMDA-MB-231H-1299HT29ovarian cancer cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

SNS-314 mesylate

Customer Review

Other Forms of SNS-314 mesylate:

SNS-314 mesylate Related Antibodies

2 Publications Citing Use of MCE SNS-314 mesylate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Aurora Kinase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

SNS-314 mesylate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

SNS-314 mesylate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report